SHEILA SPEARS: Open Payments
NPI 1447711833 · BROWNWOOD, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$768 in 37 payments from 15 companies in 2025. Trend: 2023 $93 · 2024 $595 · 2025 $768
Food & beverage: $768
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 4 | $137 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $110 |
| RECORDATI_RARE_DISEASES_INC. | 1 | $97 |
| ABBVIE INC. | 4 | $85 |
| Novo Nordisk Inc | 5 | $76 |
| Dexcom, Inc. | 3 | $57 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 4 | $33 |
| AstraZeneca Pharmaceuticals LP | 2 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
Products named: JARDIANCE, Epclusa, PANHEMATIN, Dexcom G6 Transmitter, VRAYLAR, Ozempic, Kerendia, VOQUEZNA.
Industry payments across TX — which companies pay providers there.
